University of New Mexico Cancer Center Support

新墨西哥大学癌症中心及其联盟机构-洛夫莱斯呼吸研究所、洛斯阿拉莫斯国家实验室和桑迪亚国家实验室--为广阔而美丽的地理区域服务，具有丰富的多元文化和多种族多样性，具有巨大的科学机会，具有挑战性的健康和社会经济差距，将在癌症研究方面取得重大进展，并为我们的社区和我们的国家服务。作为方圆500英里内唯一的NCI癌症中心，UNM癌症中心的特色包括：它所服务的多种族和多文化人口--主要是西班牙裔/拉丁裔、美国印第安人和非西班牙裔白人--他们的癌症发病率、死亡率和差异模式截然不同；将工程、生物技术、纳米技术、放射性同位素、药物发现、成像和高性能计算方面的地区科学优势整合到其研究计划和共享资源中；以及它为提供癌症护理、适合文化背景的社区教育和参与性研究以及社区肿瘤学家参与UNM癌症中心临床试验而建立的广泛的全州外联网络。自2005年NCI P30 CCSG上一次审查以来，该中心的年度同行评议研究资金增加了40%，总成本超过4680万美元，而NCI的年度资金增加了30%，达到1380万美元以上。中心117个成员之间的方案内和方案间协作有 在4个研究项目中，每个项目的增长幅度从20%到48%不等：癌症人口科学， 癌症生物学和生物技术、血液恶性肿瘤和女性癌症。癌症中心成员 领导美国国立卫生研究院资助的9个高通量目标筛选和分子发现路线图中心之一 [U54MH084690]，NIH资助的10个国家系统生物学中心之一(P50GM085273)，4个NSF/NCI之一 该中心是LLS 20个专门的白血病研究中心之一(LLS SCOR 7388-06)，以及一个跨学科的HPV预防中心(NIH U19AI084081)。为了确保所有新墨西哥人都能获得出色的癌症诊断和治疗，新墨西哥州癌症中心开设了面积为206,432平方米的新中心。金融时报，9000万美元，癌症治疗和临床研究设施，2009年8月，作为新墨西哥州全州癌症护理网络的枢纽。与西门子合作，这个新设施包括一个放射性同位素生产实验室和实验放射性药物，这将加速该中心的研究计划。自2009年7月1日至2009年7月1日，新墨西哥大学癌症中心在坚持其服务不足和未参保人群使命的同时，在该中心治疗的2640名新确诊患者中，有443人(17%)接受了治疗临床试验，其中51%是西班牙裔或美国印第安人。社区附属机构又招募了101名患者参加UNM治疗试验。此外，该中心在这段时间内有845项非干预方案的应计项目。新墨西哥州大学癌症中心的总体目标是：1)以我们独特的科学和区域优势为基础，在我们的实验室、诊所、多种族和多文化社区开展杰出的跨学科研究；2)通过发现导致美国西南部人民癌症模式和癌症差异的遗传、环境、社会和行为因素，降低癌症发病率和死亡率的负担；3)将我们的科学发现转化为新的诊断、筛查、预防和治疗工具和临床试验；以及4)为所有新墨西哥人提供获得杰出癌症治疗和临床试验的机会。

Serving a vast geographic region of great beauty, with rich multicultural and multiethnic diversity, tremendous scientific opportunity, and challenging health and socioeconomic disparities, the University of New Mexico Cancer Center and its consortium institutions - Lovelace Respiratory Research Institute, Los Alamos National Laboratory, and Sandia National Laboratories - are uniquely poised to make significant advances in cancer research and to serve our communities and our nation. As the only NCI Cancer Center within a 500 mile radius, the special characteristics of the UNM Cancer Center include: the multiethnic and multicultural populations that it serves - primarily Hispanic/Latino, American Indian, and non-Hispanic White - with their strikingly different patterns of cancer incidence, mortality, and disparity; the integration of regional scientific strengths in engineering, biotechnology, nanotechnology, radioisotopes, drug discovery, imaging, and high performance computing into its Research Programs and Shared Resources; and the extensive statewide outreach networks it has built for the delivery of cancer care, for culturally appropriate community-based education and participatory research, and for the participation of community oncologists in UNM Cancer Center clinical trials. Since the previous NCI P30 CCSG review in 2005, the Center's annual peer-reviewed research funding has increased 40% to over $46.8 million dollars in total costs, while annual funding from NCI increased 30% to over $13.8 million dollars. Intra-programmatic and inter-programmatic collaborations among the 117 members of the Center have increased markedly and range from 20-48% in each of the 4 Research Programs: Cancer Population Sciences, Cancer Biology and Biotechnology, Hematologic Malignancies, and Women's Cancers. Cancer Center members lead one of 9 NIH-funded Roadmap Centers for High Throughput Target Screening and Molecular Discovery {U54MH084690), one of 10 NIH-funded National Centers for Systems Biology (P50GM085273), one of 4 NSF/NCI Centers for Integrative Nanoscience and Microsystems Training (DGE0504276), one of 20 LLS Specialized Centers of Leukemia Research (LLS SCOR 7388-06), and an Interdisciplinary HPV Prevention Center (NIH U19AI084081). To assure that all New Mexicans have access to outstanding cancer diagnosis and treatment, the UNM Cancer Center opened its new 206,432 sq. ft., $90 million, Cancer Treatment and Clinical Research Facility in August 2009 which serves as the hub of the UNM Statewide Cancer Care Network. In collaboration with Siemens, this new facility contains a radioisotope production laboratory and experimental radiopharmacy, which will accelerate the Center's research programs. From 7/1/08-7/1/09, while maintaining its mission to the underserved and uninsured, the UNM Cancer Center ccrued 443 (17%) of the 2640 newly diagnosed patients treated at the Center to therapeutic clinical trials; 51% of these patients were Hispanic or American Indian. Community affiliates accrued another 101 patients to UNM therapeutic trials. In addition, the Center had 845 accruals to non-intervention protocols in this time period. The overall goals of the UNM Cancer Center are to: 1) conduct outstanding transdisciplinary research in our laboratories, clinics and multiethnic and multicultural communities that builds upon our unique scientific and regional strengths; 2) reduce the burden of cancer incidence and mortality by discovering the genetic, environmental, social, and behavioral factors that contribute to the distinct cancer patterns and cancer disparities in the peoples of the American Southwest; 3) translate our scientific discoveries to novel diagnostic, screening, prevention, and therapeutic tools and clinical trials; and 4) provide access to outstanding cancer treatment and clinical trials for all New Mexicans.